212890-85-2

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a building block for the synthesis of pharmaceuticals and agrochemicals. Its chiral nature makes it a valuable intermediate in the production of optically pure compounds, which are essential for the development of effective and safe drugs.
Used in Chemical Reactions:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a chiral reagent and a solvent in various chemical reactions. Its unique structure and properties allow it to facilitate and enhance the efficiency of these reactions, making it an important component in the field of organic synthesis.
Used in Organic Synthesis:
(2S)-4,4-dimethyl-2-pyrrolidinemethanol is used as a versatile and important chemical in the field of organic synthesis. Its pyrrolidine ring structure and two methyl groups provide a foundation for the development of new compounds and materials, contributing to advancements in chemistry and related industries.

Upstream product

• 156088-46-9 (5S)-3,3-dimethyl-5-hydroxymethylpyrrolidin-2-one 
• 1094359-30-4 1-[4,4-dimethyl-1-(toluene-4-sulfonyl)-pyrrolidin-2-ylmethoxy]-2,2,6,6-tetramethyl-piperidine 
• 158392-80-4 1-tert-butyl 2-ethyl (2S)4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 
• 221637-35-0 (S)-ethyl 4,4-dimethyl-5-oxopyrrolidine-2-carboxylate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 156088-45-8 (5S)-1-aza-2,2-dimethyl-7,7-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane 
• 99208-71-6 (5S)-1-aza-2,2-dimethyl-3-oxa-8-oxo-bicyclo[3.3.0]octane 

Downstream Products

• 212890-84-1 (S)-2-[(Diphenylphosphanyl)-methyl]-4,4-dimethyl-pyrrolidine 
• 184699-47-6 (S)-(-)-tert-butyl 4,4-dimethyl-2-[((4-methylphenyl)sulfonyloxy)methyl]pyrrolidinecarboxylate 
• 212890-87-4 (S)-(-)-tert-butyl 2-[(diphenylphosphino)methyl]-4,4-dimethylpyrrolidinecarboxylate 
• 891183-50-9 4,4-dimethyl-L-proline 
• 443984-28-9 (S)-(N-benzyloxycarbonyl)-(4,4-dimethylpyrrolidin-2-yl)methan-1-ol 
• 212890-86-3 (S)-(-)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidinecarboxylate 

Relevant academic research and scientific papers

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION

Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

4,4′-Disubstituted L-prolines as highly enantioselective catalysts for direct aldol reactions

A new series of 4,4′-disubstituted prolines (1a-h) has been developed and tested as organocatalysts in the direct catalytic asymmetric aldol reaction of several aliphatic ketones with aldehydes. Catalyst 1g affords the best enantioselectivities for this transformation. The reaction was carried out in DMF using a catalyst loading of 10 mol% at -10°C to give the aldol products in up to 97% ee for acetone. In the cases of cyclohexanone and cyclopentanone, the corresponding anti-products were obtained in 94% ee.

An external chiral amidophosphine ligand for asymmetric conjugate addition of organocopper

Two types of external, chiral amidophosphine ligands, 1-5, were prepared. Examination of their behavior in an asymmetric conjugate addition reaction of organocuprate revealed the possibility for steric tuning to realize high selectivity.

Structural requirements of an external, chiral amidophosphine ligand for asymmetric reaction of an organocopper reagent

Three types of an external, chiral amide ligand, 2-6, were prepared and examination of their behavior in an asymmetric conjugate addition reaction of lithium dimethylcuprate with chalcone revealed to possibility for steric tuning to realize high selectivity.